Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Vaccination Response in Healthy Subjects
NCT02543918Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ixekizumab in plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations at Week 6. Started Sep 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02543918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543918.